Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)

Author： Emkey Ronald   Koltun William   Beusterien Kathleen   Seidman Larry   Kivitz Alan   Devas Vipul   Masanauskaite Daiva  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.21, Iss.12, 2005-12, pp. : 1895-1903

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

By Miller Paul D.   Epstein Sol   Sedarati Farhad   Reginster Jean-Yves  

Current Medical Research and Opinion, Vol. 24, Iss. 1, 2008-01 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

By Sebba Anthony I.   Bonnick Sydney Lou   Kagan Risa   Thompson Desmond E.   Skalky Carol S.   Chen Erluo   de Papp Anne E.    

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2031-2041

Informa Healthcare

Access to resources Recommend Favorite

Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment

By Emkey Ronald  

Women's Health, Vol. 2, Iss. 3, 2006-05 ,pp. : 341-349

Future Medicine

Access to resources Recommend Favorite

Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget’s disease

By Hooper M.   Faustino A.   Reid I.   Hosking D.   Gilchrist N.   Selby P.   Wu M.   Salzmann G.   West J.   Leung A.  

Osteoporosis International, Vol. 20, Iss. 1, 2009-01 ,pp. : 141-150

Springer Publishing Company

Access to resources Recommend Favorite

Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial

By Recker Robert   Lips Paul   Felsenberg Dieter   Lippuner Kurt   Benhamou Laurent   Hawkins Federico   Delmas Pierre D.   Rosen Clifford   Emkey Ronald   Salzmann Gretel   He Weili   Santora Arthur C.  

Current Medical Research and Opinion, Vol. 22, Iss. 9, 2006-09 ,pp. : 1745-1755

Informa Healthcare

Access to resources Recommend Favorite